Tumor Reduction with Pazopanib in a Patient with Recurrent Lumbar Chordoma

<div>Histopathologic and immunohistochemical evaluation. (a) Chordoma with expansive invasion (hematoxylin-eosin–HE, 10x). (b) Epithelioid eosinophilic cells in myxoid matrix (HE, 200x); (c) INI-1 positive/preserved expression in neoplastic cells (immunohistochemistry, 200x); (d) Ki-67 positive in neoplastic cells (immunohistochemistry, 200x).</div>

Case Reports in Oncological Medicine

fig1

Figure 1

Figure 1: Tumor Reduction with Pazopanib in a Patient with Recurrent Lumbar Chordoma 